Skip to Content

Ubrogepant Dosage

Medically reviewed by Drugs.com. Last updated on March 3, 2020.

Applies to the following strengths: 50 mg; 100 mg

Usual Adult Dose for Migraine

Initial dose: 50 to 100 mg orally, once
-After 2 hours, a second dose may be taken if needed
Maximum dose: 200 mg in 24-hour period

Comments:
-The safety of treating more than 8 migraines in a 30-day period is unknown.

Use: For the acute treatment of migraine with or without aura.

Renal Dose Adjustments

Mild or moderate renal impairment: No adjustment recommended
Severe renal impairment (CrCl 15 to 29 mL/min): Initial dose: 50 mg orally once; a second 50 mg dose may be taken after 2 hours, if needed; Maximum dose: 100 mg in 24-hours
ESRD (CrCl less than 15 mL/min): Avoid use

Liver Dose Adjustments

Mild or Moderate Hepatic Impairment (Child-Pugh A or B): No adjustment recommended
Severe Hepatic Impairment (Child-Pugh C): Initial dose: 50 mg orally once; a second 50 mg dose may be taken after 2 hours, if needed; Maximum dose: 100 mg in 24-hours

Dose Adjustments

Elderly: Dose selection should be cautious, consider starting at the low end of the dosing range

Concomitant Use with CYP450 3A4 Inhibitors:
-With Strong CYP450 3A4 Inhibitors: Contraindicated
-With Moderate CYP450 3A4 Inhibitors: 50 mg orally once in 24 hours
-With Weak CYP450 3A4 Inhibitors: Initial dose: 50 mg orally once; a second 50 mg dose may be taken after 2 hours, if needed; Maximum dose: 100 mg in 24-hours

Concomitant Use with CYP450 3A4 Inducers:
-With Strong CYP450 3A4 Inducers: Avoid concomitant use
-With Weak and Moderate CYP450 3A4 Inducers: Initial dose: 100 mg orally once; a second dose of 100 mg may be taken 2 hours after initial dose

Concomitant Use with BCRP and/or P-gp Only Inhibitors: Initial dose: 50 mg orally once; a second 50 mg dose may be taken after 2 hours, if needed

Precautions

CONTRAINDICATIONS:
-Concomitant use of strong CYP450 3A4 inhibitors

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Take orally with or without food

General:
-This drug is the first oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should understand that this drug interacts with a number of other drugs and it is important to report all other medications being used, including over the counter and herbal products; dose modifications may be necessary.
-Patients should be instructed to avoid grapefruit juice during therapy.
-Patients who are pregnant or planning to become pregnant should discuss this with their healthcare provider.
-Patients who are breastfeeding or planning to breastfeed should discuss this with their healthcare provider.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about ubrogepant

Consumer resources

Other brands: Ubrelvy

Professional resources

Related treatment guides